HC Wainwright Predicts Talphera FY2026 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Stock analysts at HC Wainwright issued their FY2026 EPS estimates for Talphera in a research report issued to clients and investors on Friday, June 5th. HC Wainwright analyst B. Folkes expects that the company will post earnings of ($0.26) per share for the year. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. HC Wainwright also issued estimates for Talphera’s FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $0.13 EPS.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03.

Other analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a report on Monday, April 20th. Westpark Capital initiated coverage on Talphera in a report on Thursday, April 30th. They set a “buy” rating and a $3.00 price objective for the company. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.00.

Talphera Trading Up 9.3%

Shares of TLPH opened at $0.85 on Tuesday. Talphera has a 12 month low of $0.38 and a 12 month high of $1.57. The stock has a fifty day moving average price of $0.81 and a 200-day moving average price of $0.94. The firm has a market cap of $43.95 million, a PE ratio of -2.73 and a beta of 0.76.

Insider Activity

In other news, CEO Vincent J. Angotti bought 213,310 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $0.59 per share, with a total value of $125,852.90. Following the transaction, the chief executive officer directly owned 800,705 shares in the company, valued at approximately $472,415.95. The trade was a 36.31% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Talphera

Hedge funds have recently made changes to their positions in the company. Group One Trading LLC increased its position in shares of Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after acquiring an additional 29,500 shares during the period. Virtu Financial LLC acquired a new position in shares of Talphera in the 3rd quarter valued at $29,000. Persistent Asset Partners Ltd purchased a new stake in Talphera in the fourth quarter valued at $42,000. Mariner LLC boosted its holdings in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the last quarter. Finally, Dauntless Investment Group LLC purchased a new stake in Talphera in the third quarter valued at $89,000. 37.67% of the stock is owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.